Incidence of Meningococcal Disease Before and After Implementation of Quadrivalent Meningococcal Conjugate Vaccine in the United States | Zendy

Sarah Mbaeyi | Zendy; Tracy Pondo | Zendy; Amy Blain | Zendy; David Yankey | Zendy; Caelin Cubeñas-Potts | Zendy; Amanda Cohn | Zendy; Susan Hariri | Zendy; g Shang | Zendy; Jessica R. MacNeil | Zendy

Open Access

Incidence of Meningococcal Disease Before and After Implementation of Quadrivalent Meningococcal Conjugate Vaccine in the United States

Author(s) -

Sarah Mbaeyi,

Tracy Pondo,

Amy Blain,

David Yankey,

Caelin Cubeñas-Potts,

Amanda Cohn,

Susan Hariri,

g Shang,

Jessica R. MacNeil

Publication year - 2020

Publication title -

jama pediatrics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.004

H-Index - 183

eISSN - 2168-6211

pISSN - 2168-6203

DOI - 10.1001/jamapediatrics.2020.1990

Subject(s) - medicine , meningococcal vaccine , meningococcal disease , vaccination , incidence (geometry) , neisseria meningitidis , booster dose , pediatrics , poisson regression , population , booster (rocketry) , immunization , conjugate vaccine , immunology , environmental health , antibody , physics , astronomy , biology , bacteria , optics , genetics

In 2005, the US Advisory Committee on Immunization Practices recommended routine quadrivalent meningococcal conjugate (MenACWY) vaccine for all adolescents aged 11 to 12 years, and in 2010, a booster dose for adolescents aged 16 years. Measuring the association between MenACWY vaccination and the incidence of meningococcal disease in adolescents is critical for evaluating the adolescent vaccination program and informing future vaccine policy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research